Abstract: The present invention relates to a sulfate crystal form of a compound represented by formula 1, a method of producing same, and a pharmaceutical composition comprising same. The sulfate crystal form of the compound represented by formula 1 of the present invention may be characterized by an XRPD pattern, a DSC profile, and/or a TGA profile.
| # | Name | Date |
|---|---|---|
| 1 | 202317073741-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [30-10-2023(online)].pdf | 2023-10-30 |
| 2 | 202317073741-STATEMENT OF UNDERTAKING (FORM 3) [30-10-2023(online)].pdf | 2023-10-30 |
| 3 | 202317073741-PROOF OF RIGHT [30-10-2023(online)].pdf | 2023-10-30 |
| 4 | 202317073741-POWER OF AUTHORITY [30-10-2023(online)].pdf | 2023-10-30 |
| 5 | 202317073741-FORM 1 [30-10-2023(online)].pdf | 2023-10-30 |
| 6 | 202317073741-DRAWINGS [30-10-2023(online)].pdf | 2023-10-30 |
| 7 | 202317073741-DECLARATION OF INVENTORSHIP (FORM 5) [30-10-2023(online)].pdf | 2023-10-30 |
| 8 | 202317073741-COMPLETE SPECIFICATION [30-10-2023(online)].pdf | 2023-10-30 |
| 9 | 202317073741-MARKED COPIES OF AMENDEMENTS [06-11-2023(online)].pdf | 2023-11-06 |
| 10 | 202317073741-FORM 13 [06-11-2023(online)].pdf | 2023-11-06 |
| 11 | 202317073741-AMMENDED DOCUMENTS [06-11-2023(online)].pdf | 2023-11-06 |
| 12 | 202317073741-FORM 18 [07-11-2023(online)].pdf | 2023-11-07 |
| 13 | 202317073741-FORM 3 [30-05-2024(online)].pdf | 2024-05-30 |
| 14 | 202317073741-FORM 3 [28-11-2024(online)].pdf | 2024-11-28 |